3-year update on the ELOQUENT-2 clinical trial of elotuzumab in multiple myeloma

Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented at the American Society of Hematology (ASH) 2015 Annual Meeting, on the ELOQUENT-2 clinical trial of elotuzumab in combination with lenalidomide and dex­a­meth­a­sone in multiple myeloma. The study demonstrated a sustained progression-free survival (PFS) benefit to patients in the elotuzumab arm, when compared to placebo in relapsed/refractory myeloma.